Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
· Issued by Organogenesis Holdings Inc.
- Statistically significant (p=0.0177) reduction in knee pain at six months
- Statistically significant (p
Company analysis
